MONDAY, July 1, 2019 (HealthDay News) — Regardless of test results, 94 percent of women undergoing preimplantation genetic testing for aneuploidy (PGT-A) were satisfied with their decision, according to a study published online June 21 in Human Reproduction.

Kara N. Goldman, from New York University in New York City, and colleagues conducted an anonymous survey of 395 patients who underwent their first cycle of autologous PGT-A between January 2014 and March 2015 at a university-affiliated fertility center.

Based upon 69 responses, the authors report the respondents most commonly utilized PGT-A on their first IVF cycle to “maximize the efficiency of IVF” or reduce per-transfer miscarriage risk. While the median Brehaut Decision Regret Scale score was low, 39 percent of respondents expressed some degree of regret. Multiple regression analysis showed a relationship between embryo ploidy and decision regret, with a lower number of euploid embryos associated with a greater degree of regret. There was less reported regret among patients who conceived following euploid transfer versus those who miscarried or failed to conceive (P < 0.005). There was no association between decision regret and age, education, race, insurance coverage, religion, marital status or reason for having IVF/PGT-A, although there was an inverse association with number of living children. There was a negative association between anxiety and age, time since oocyte retrieval, and number of living children.

“Overall, decision regret was low, and 94 percent of all respondents reported satisfaction with their decision to pursue PGT-A, but patients with a negative outcome were more likely to express decision regret and anxiety,” conclude the authors.

One author reports ties to the pharmaceutical industry and reproductive medicine institutes.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.